Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2016). ![]() (GPL) is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. Supplement and accelerate the growth of its existing pipeline and portfolio. Internal filings, Glenmark continues to identify and explore external development partnerships to marketplaceĪnd 64 ANDA’s pending approval with the U.S. Glenmark’s current portfolio consists of 111 products authorized for distribution in the U.S. “Par remains committed to providing patients access to high quality and affordable medicines.” “We, along with our partners at Glenmark, are proud to be able to offer patients managing theirĬholesterol levels the first generic version of ZETIA®,” said Tony Pera, President of Par Pharmaceutical. Only underscores our joint commitment to bridging the gap between patients and the medicines they “Our partnership with Par to bring the first generic version of ZETIA® to market The world,” said Robert Matsuk, President of North America and Global API at Glenmark “Glenmark has a deep heritage of bringing safe, effective and affordable medicines to patients around (heterozygous familial and non-familial) hyperlipidemia.Īccording to IMS Health data for the 12-month period ending October 2016, annual U.S. Glenmark and its partner, Endo will be entitled to 180 days of generic drug exclusivity for ezetimibe as provided for under section 505(j)(5)(B)(iv) of the FD&C Act.Įzetimibe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-Ĭ), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary The availability of ezetimibe is the result of a licensing partnership with Par Pharmaceutical, an Endo International plc operating company, with whom Glenmark will share profits. Mumbai, India December 12, 2016: Glenmark Pharmaceuticals Inc., USA today announced the availability of ezetimibe, the first and only generic version of ZETIA® (Merck) in the United States for the treatment of high cholesterol. Glenmark Launches First and Only Generic Version of Zetia® in the United States “We have launched ezetimibe, the first and only generic version of Zetia (Merck) in the United States for the treatment of high cholesterol,”………. Tropical Disease Priority Review Voucher.Investigational device exemption (IDE) approval.Human medicines European Public Assessment Report EPAR.The alleged shift, or “product hop,” occurred shortly before the generics were preparing to come to market. The alleged scheme involved the introduction of a film version of Suboxone and shifting the pill customer base to this new market. created an anticompetitive scheme to keep Suboxone generic rivals off the market. ![]() Plaintiffs allege that Reckitt Benckiser Inc. and others filed sham patent litigations and entered into “reverse payment agreements” to induce generic companies to stay out of the market. Plaintiffs allege that Medicis Pharmaceutical Corp. Plaintiffs allege that Cephalon unlawfully protected its Provigil monopoly through a series of agreements with four generic manufacturers in which the generic companies were paid over $300 million to delay market entry for six years. and Teva Pharmaceuticals entered a prohibited “reverse payment agreement” in which the branded manufacturer paid the generic to stay off the market for eight years. entered into unlawful “reverse payment agreements” to delay generic entry of WC’s oral contraceptive – Loestrin. Plaintiffs allege that Warner Chilcott (“WC”), Watson Pharmaceuticals Inc. Endo allegedly gave between $96 million and $240 million worth of free Lidoderm branded product to induce Actavis to delay market entry for one year. entered into an unlawful “reverse payment agreement” to delay generic competition for the drug Lidoderm. ![]() Plaintiffs allege that Endo Pharmaceuticals and Actavis Inc. Our antitrust team has experience in pursuing antitrust class actions related to pharmaceutical drugs and is currently involved in the following cases: Lidoderm Antitrust lawyers with Motley Rice have been challenging these practices for more than 16 years on behalf of health insurers and consumers in an effort to hold prescription drug manufacturers accountable and deter such conduct in the future.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |